Oncolytic Virotherapy for Multiple Myeloma: Past, Present, and Future
Open Access
- 10 May 2011
- journal article
- review article
- Published by Hindawi Limited in Bone Marrow Research
- Vol. 2011, 1-10
- https://doi.org/10.1155/2011/632948
Abstract
Multiple myeloma (MM) is a B-cell malignancy that is currently felt to be incurable. Despite recently approved novel targeted treatments such as lenalidomide and bortezomib, most MM patients' relapse is emphasizing the need for effective and well-tolerated therapies for this deadly disease. The use of oncolytic viruses has garnered significant interest as cancer therapeutics in recent years, and are currently under intense clinical investigation. Both naturally occurring and engineered DNA and RNA viruses have been investigated preclinically as treatment modalities for several solid and hematological malignancies. Presently, only a genetically modified measles virus is in human clinical trials for MM. The information obtained from this and other future clinical trials will guide clinical application of oncolytic viruses as anticancer agents for MM. This paper provides a timely overview of the history of oncolytic viruses for the treatment of MM and future strategies for the optimization of viral therapy for this disease.Keywords
This publication has 88 references indexed in Scilit:
- Treatment-related peripheral neuropathy in multiple myeloma: the challenge continuesThe Lancet Oncology, 2010
- Infection and Killing of Multiple Myeloma by AdenovirusesHuman Gene Therapy, 2010
- Cyclophosphamide Facilitates Antitumor Efficacy against Subcutaneous Tumors following Intravenous Delivery of ReovirusClinical Cancer Research, 2008
- Preclinical Pharmacology and Toxicology of Intravenous MV-NIS, an Oncolytic Measles Virus Administered With or Without CyclophosphamideClinical Pharmacology & Therapeutics, 2007
- Radioiodide imaging and radiovirotherapy of multiple myeloma using VSV(Δ51)-NIS, an attenuated vesicular stomatitis virus encoding the sodium iodide symporter geneBlood, 2007
- Infected Cell Carriers: A New Strategy for Systemic Delivery of Oncolytic Measles Viruses in Cancer VirotherapyMolecular Therapy, 2007
- Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)–dependent migration and homing in multiple myelomaBlood, 2006
- Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responsesProceedings of the National Academy of Sciences of the United States of America, 2006
- Myeloma cell contamination of peripheral blood stem-cell grafts can predict the outcome in multiple myeloma patients after high-dose chemotherapy and autologous stem-cell transplantationZeitschrift für Krebsforschung und Klinische Onkologie, 2004
- Variation in survival of adult patients with haematological malignancies in Europe since 1978European Journal of Cancer, 1998